AlphAIalphai — Financial news for AI agents
The Chronicle-JournalMAY 203 min read$AIRS

AirSculpt Technologies, Inc. - Common Stock (Nasdaq:AIRS) Stock Quote

This article provides a stock quote for AirSculpt Technologies, Inc. (NASDAQ:AIRS), showing its current trading price, volume, and performance metrics. It also includes recent news headlines about the company's Q1 earnings, sales rebound with GLP-1 tailwind for body contouring growth, and previous financial reports and analyst insights. The information covers detailed quote data, historical prices, and frequently asked questions about the stock.

Original reporting
The Chronicle-Journal
Published May 20, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 20, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$AIRS
Bullish
medium confidence
Mentioned
$AIRS
alphai data visualization · based on The Chronicle-Journal
Decision brief

The 30-second read

$AIRSBullishMed
01

Why it matters

The positive earnings report and sales rebound suggest a favorable outlook, but market volatility warrants caution.

02

Market read

The news is relevant for traders focusing on the healthcare and medical aesthetics sectors, especially those with a short to medium-term investment horizon.

03

What to watch

Potential regulatory changes or macroeconomic factors could adversely affect the company's performance.

Timing: Immediate to short-term (next 1-3 months)

Background

AirSculpt Technologies has recently reported Q1 earnings showing improved sales, supported by industry tailwinds such as increased demand for body contouring procedures.

Company-level read

Ticker impact

$AIRSBullishMedium confidence
Context

The article provides recent updates on AirSculpt Technologies, Inc., including earnings and sales performance, which are relevant for short-term and medium-term trading decisions.

Expected impact

Moderate increase (~5-8%) over the next 1-3 months

Evidence & confidence

Recent earnings beat expectations and industry tailwinds support growth; however, market volatility and sector-specific risks introduce uncertainty.

Market effects

Sector

The medical aesthetics and life sciences sectors may experience positive sentiment, potentially benefiting similar companies.

Regional

Primarily US-focused, with limited immediate impact on international markets.

Global

Low; company-specific news with limited global implications.

Counterpoint

What could challenge this read

The positive news may already be priced in, and sector rotation or profit-taking could lead to short-term declines.

Key entities

  • Company
    AirSculpt Technologies, Inc.

    A provider of minimally invasive body contouring procedures.

Read at source← All news

Related articles

AUG 17
$AIRSMedAI 8/10

AirSculpt (AIRS) Q2 2026 Earnings Call Transcript

AirSculpt Technologies (AIRS) reported Q2 2026 revenue of $42.9M, down 3% from $44.0M a year earlier. Q2 case volume was 3,376, slightly down, while gross margin rose to 61.2%. Adjusted EBITDA was $4.9M. Full-year revenue guidance is $151M to $157M and Adjusted EBITDA $12M to $14M, revised lower on added marketing. Cash was $18.8M; debt was $44.2M.

fool.com6 min
AUG 10
$TENXHighAI 8/10

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.

investing.com7 min
AUG 10
$AIRSHighAI 9/10

Why is AirSculpt Technologies stock tumbling today?

Investing.com reports AirSculpt Technologies (AIRS) shares fell about 18.4% in pre-open after its Q2 fiscal 2026 earnings. Revenue was $42.9M, down 3% YoY, with net loss of $1.1M and Adjusted EBITDA $4.9M (11.5% margin). Guidance was revised to the lower end of $151–$157M revenue and Adjusted EBITDA $12–$14M.

investing.com4 min
AUG 10
$AIRSMed

Airsculpt Technologies, Inc. (AIRS): Results of Operations and Financial Condition

Airsculpt Technologies, Inc. (AIRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results Same Center Cases Up 1% for the Second Consecutive Quarter MIAMI BEACH, Fla., August 10, 2026 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national pro

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min